| INTRODUCTION
Synovial sarcoma (SS) is rare but a highly aggressive soft-tissue sarcoma (STS) that can develop at any site in the body but often arises at lower extremities in adolescents and young adults. 1, 2 Although cases with a resectable SS have a relatively better prognosis, there remains a high risk of local recurrence and metastasis to the lymph nodes and lung. Patients with metastatic SS have a poor prognosis. 3, 4 Although the molecular mechanisms underlying the oncogenesis of SS have remained elusive, a balanced t(X,18; p11,q11) chromosomal translocation is found in virtually all cases, which creates a fusion oncogene, SS18-SSX, that could be the driver mutation gene for these cancers. 5, 6 Surgical therapy, accompanied by radiation and/or chemotherapy, has been shown to be effective for early stage SS but no effective therapies have been established so far for advanced SS. Novel therapeutic strategies for this disease are, thus, highly desired.
Frizzled homolog 10 (FZD10) is a transmembrane protein member of the Frizzled family 7 and serves as a putative receptor in the Wnt signal pathway. Previous studies have revealed that FZD10 is highly expressed in SS tumors and cell lines but is absent in most normal tissues, and that immunotherapy using an antibody against FZD10 inhibits the growth of SS xenografts. 8, 9 Furthermore, radioimmunotherapy (RIT) using a yttrium-90 ( 90 Y)-labeled anti-FZD10 antibody emitting b-particle radiation has been reported to be effective against SS in a preclinical mouse model. 10, 11 These studies raised the possibility that FZD10 has potential as a therapeutic target for SS.
Recently, a-particle-based RIT (a-RIT) has emerged as a novel antitumor strategy. Astatine-211 ( 211 At) is one of the more attractive a-emitters in this regard because of its 7.2-h half-life and 100% aparticle emission during its decay. 12 The remarkably high cell killing potency of 211 At derives from its high energy transfer within a short range of the a-particle, which is considered to be stronger than that of a b-particle. 13 We have previously reported, also in a preclinical mouse model, that a-RIT using 211 At-labeled trastuzumab is highly effective against peritoneal metastases of gastric cancers that are positive for human epidermal growth factor receptor 2 (HER2).
14 Thus, we speculated that a-RIT may be more beneficial than b-RIT in the treatment of solid tumors, including STS and SS, which are often radio-resistant or chemo-resistant. This notion is supported by the findings of several previous studies of solid tumor models. 15, 16 However, few reports to date have directly compared the therapeutic efficacy of a-RIT and b-RIT against SS in vivo.
In our current study, we conducted comparative analysis of a-
RIT using a 211
At-anti-FZD10 antibody and b-RIT using a 90 Y-anti-FZD10 antibody in a preclinical SS xenograft model and evaluated both their therapeutic efficacy and toxicity against SS.
| MATERIALS AND METHODS

| Cells
The human synovial sarcoma cell line SYO-1 was kindly provided by Dr A. Kawai (National Cancer Center, Tokyo, Japan). 17 Cells were cultured with D-MEM medium, supplemented with 10% FBS and 1%
penicillin-streptomycin (Wako, Osaka, Japan), and maintained in a humidified atmosphere containing 5% CO 2 at 37°C.
| Reagents
A humanized chimeric anti-FZD10 antibody, OTSA101, was provided by
OncoTherapy Science (Kanagawa, Japan). N-succinimidyl-3-(trimethylastannyl) benzoate (m-MeATE) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA) and stored at À30°C. N-chlorosuccinimide (NCS) was purchased from Tokyo Chemical Industry (Tokyo, Japan).
| Radiolabeling of the anti-FZD10 antibody
Astatine-211 ( 211 At) was produced by the 209 Bi (a, 2n) 211 At reaction as described previously. 18 The 211 At labeling of anti-FZD10 antibody (OTSA101) was also carried out following a previously described procedure. 14 
| Animal experiments
All animal experiments were approved by the Animal Care and Use
Committee of the National Institute of Radiological Sciences at the LI ET AL.
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National Institutes for Quantum and Radiological Science and Technology (Chiba, Japan) and were undertaken in compliance with the institutional guidelines regarding animal care and handling.
| Tumor xenograft mouse model
The SS xenograft mouse model was established by subcutaneously implanting SYO-1 cells (1 9 10 7 cells in 0.1-mL PBS) into the flank of BALB/c nude mice (Japan SLC, Hamamatsu, Japan).
| Biodistribution
Biodistribution studies were performed as described previously. 
| Radioimmunotherapy
Radioimmunotherapy was performed as described previously. 
| Statistical analysis
Statcel 3 software (OMS, Tokorozawa, Japan) was used for all statistical analysis. Tumor volumes and survival data were analyzed using 2-way repeated measures ANOVA and the Kaplan-Meier method, respectively. A P-value of <.05 was considered significant.
| RESULTS
| Radiochemical analyses of radiolabeled OTSA101
The labeling yields of higher radioactivity was observed only for 211 At-OTSA101 at approximately a 6-fold higher level than 111 In-OTSA101 ( Figure 1A,B) .
We observed increased tumor uptake for both of the radiolabeled OTSA101 molecules over time but to different maximum levels of We next measured the animal body weights to assess the toxicity of both radiolabeled antibodies ( Figure 3 ). Although these weights tended to be lower in the mice treated with the 50-lCi doses, no apparent severe body weight loss was observed in any of the experimental animals ( Figure 3A ,B).
| Absorbed dose by the tumor following radioimmunotherapy with 211 At-OTSA101 and 90 Y-
OTSA101
The absorbed doses of the radiolabeled antibodies by each mouse tissue were calculated using biodistribution data ( 
| Histopathological features of a-RIT and b-RIT
We conducted histopathological analyses to identify any differences 
| DISCUSSION
We found in our present analyses that 211 At-OTSA101, an a-emit- In conclusion, a-RIT using 211 At-OTSA101 effectively suppresses the growth of SS xenografts in a preclinical mouse model with no apparent toxicities and with more efficiency than b-RIT using 211 Y-
OTSA101
. 211 At-OTSA101 therapy may prove to be a relatively safe and effective option for the future treatment of SS.
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